ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sanofi and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SanofiNovartis
studies on the registry2,4253,900
open to participants now105211
phase 3 studies under way6194
reach primary completion within a year64125
programswith a study of their own in two years80+12 named only77+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSanofiNovartis
Phase 128%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 2

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
Phase 3

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 26 in all. A program counts in each condition its studies name most.

ConditionSanofiNovartis
Dermatitis, Atopicboth · compare here

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

Arthritis, Rheumatoidboth · compare here

Sanofi in Arthritis, Rheumatoid: 2 programs

  1. balinatunfibphase 2
  2. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Rheumatoid in search

Novartis in Arthritis, Rheumatoid: 5 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  4. DKB903phase 1
  5. secukinumabapproved, new study

Their studies: Novartis’s studies of Arthritis, Rheumatoid in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Hidradenitis Suppurativaboth · compare here

Sanofi in Hidradenitis Suppurativa: 2 programs

  1. brivekimigphase 2
  2. zetrukibartphase 2

Their studies: Sanofi’s studies of Hidradenitis Suppurativa in search

Novartis in Hidradenitis Suppurativa: 3 programs

  1. remibrutinibphase 3
  2. arumakimigphase 2
  3. secukinumabapproved, new study

Their studies: Novartis’s studies of Hidradenitis Suppurativa in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

Sanofi in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. rilzabrutinibphase 3
  2. riliprubartphase 3

Their studies: Sanofi’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Novartis in Purpura, Thrombocytopenic, Idiopathic: 3 programs

  1. ianalumabphase 3
  2. Thrombopoietin Receptor Agonistphase 2
  3. eltrombopagapproved, new study

Their studies: Novartis’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Lupus Erythematosus, Systemicboth · compare here

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

Malariaboth · compare here

Sanofi in Malaria: 1 program

  1. Yellow Fever Vaccinephase 3

Their studies: Sanofi’s studies of Malaria in search

Novartis in Malaria: 3 programs

  1. cipargaminphase 2
  2. ganaplacidephase 2
  3. Coartem® Babyapproved, new study

Their studies: Novartis’s studies of Malaria in search

Psoriasisboth · compare here

Sanofi in Psoriasis: 3 programs

  1. balinatunfibphase 2
  2. belumosudilapproved, new study
  3. teplizumabapproved, new study

Their studies: Sanofi’s studies of Psoriasis in search

Novartis in Psoriasis: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Psoriasis in search

Alzheimer Diseaseboth · compare here

Sanofi in Alzheimer Disease: 1 program

  1. SAR448851phase 2

Their studies: Sanofi’s studies of Alzheimer Disease in search

Novartis in Alzheimer Disease: 2 programs

  1. Oligonucleotides, Antisensephase 2
  2. VHB937phase 2

Their studies: Novartis’s studies of Alzheimer Disease in search

Anemia, Sickle Cellboth · compare here

Sanofi in Anemia, Sickle Cell: 2 programs

  1. rilzabrutinibphase 3
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3

Their studies: Sanofi’s studies of Anemia, Sickle Cell in search

Novartis in Anemia, Sickle Cell: 1 program

  1. ITU512phase 2

Their studies: Novartis’s studies of Anemia, Sickle Cell in search

Hypercholesterolemiaboth · compare here

Sanofi in Hypercholesterolemia: 1 program

  1. Cholestyramine Resinphase 3

Their studies: Sanofi’s studies of Hypercholesterolemia in search

Novartis in Hypercholesterolemia: 2 programs

  1. QCZ484phase 2
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Hypercholesterolemia in search

Lymphoma, B-Cellboth · compare here

Sanofi in Lymphoma, B-Cell: 1 program

  1. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lymphoma, B-Cell in search

Multiple Myelomaboth · compare here

Sanofi in Multiple Myeloma: 1 program

  1. Anti-GPRC5D Monoclonal Antibody SAR446523phase 1

Their studies: Sanofi’s studies of Multiple Myeloma in search

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

Myotonic Dystrophyboth · compare here

Sanofi in Myotonic Dystrophy: 1 program

  1. SAR446268phase 2

Their studies: Sanofi’s studies of Myotonic Dystrophy in search

Novartis in Myotonic Dystrophy: 2 programs

  1. delpacibart zotadirsenphase 3
  2. AOC 1001phase 3

Their studies: Novartis’s studies of Myotonic Dystrophy in search

Sjogren's Syndromeboth · compare here

Sanofi in Sjogren's Syndrome: 1 program

  1. frexalimabphase 3

Their studies: Sanofi’s studies of Sjogren's Syndrome in search

Novartis in Sjogren's Syndrome: 2 programs

  1. ianalumabphase 3
  2. DDY391phase 2

Their studies: Novartis’s studies of Sjogren's Syndrome in search

Arthritis, Juvenileboth · compare here

Sanofi in Arthritis, Juvenile: 1 program

  1. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Juvenile in search

Novartis in Arthritis, Juvenile: 1 program

  1. arumakimigphase 2

Their studies: Novartis’s studies of Arthritis, Juvenile in search

Bronchiolitis Obliterans Syndromeboth · compare here

Sanofi in Bronchiolitis Obliterans Syndrome: 1 program

  1. belumosudilapproved, new study

Their studies: Sanofi’s studies of Bronchiolitis Obliterans Syndrome in search

Novartis in Bronchiolitis Obliterans Syndrome: 1 program

  1. asciminibapproved, new study

Their studies: Novartis’s studies of Bronchiolitis Obliterans Syndrome in search

Carcinoma, Renal Cellboth · compare here

Sanofi in Carcinoma, Renal Cell: 1 program

  1. Biological Productsphase 1

Their studies: Sanofi’s studies of Carcinoma, Renal Cell in search

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

Chronic Urticariaboth · compare here

Sanofi in Chronic Urticaria: 1 program

  1. BLU-808phase 2

Their studies: Sanofi’s studies of Chronic Urticaria in search

Novartis in Chronic Urticaria: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Chronic Urticaria in search

Colorectal Neoplasmsboth · compare here

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Geographic Atrophyboth · compare here

Sanofi in Geographic Atrophy: 1 program

  1. SAR446597phase 2

Their studies: Sanofi’s studies of Geographic Atrophy in search

Novartis in Geographic Atrophy: 1 program

  1. FWY003phase 2

Their studies: Novartis’s studies of Geographic Atrophy in search

Macular Degenerationboth · compare here

Sanofi in Macular Degeneration: 1 program

  1. SAR402663phase 2

Their studies: Sanofi’s studies of Macular Degeneration in search

Novartis in Macular Degeneration: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Macular Degeneration in search

Polycystic Kidney, Autosomal Dominantboth · compare here

Sanofi in Polycystic Kidney, Autosomal Dominant: 1 program

  1. venglustatphase 3

Their studies: Sanofi’s studies of Polycystic Kidney, Autosomal Dominant in search

Novartis in Polycystic Kidney, Autosomal Dominant: 1 program

  1. farabursenphase 1

Their studies: Novartis’s studies of Polycystic Kidney, Autosomal Dominant in search

Pulmonary Arterial Hypertensionboth · compare here

Sanofi in Pulmonary Arterial Hypertension: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Pulmonary Arterial Hypertension in search

Novartis in Pulmonary Arterial Hypertension: 1 program

  1. LTP001phase 2

Their studies: Novartis’s studies of Pulmonary Arterial Hypertension in search

Scleroderma, Diffuseboth · compare here

Sanofi in Scleroderma, Diffuse: 1 program

  1. belumosudilapproved, new study

Their studies: Sanofi’s studies of Scleroderma, Diffuse in search

Novartis in Scleroderma, Diffuse: 1 program

  1. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Scleroderma, Diffuse in search

Spondylitis, Ankylosingboth · compare here

Sanofi in Spondylitis, Ankylosing: 1 program

  1. sarilumabapproved, new study

Their studies: Sanofi’s studies of Spondylitis, Ankylosing in search

Novartis in Spondylitis, Ankylosing: 1 program

  1. secukinumabapproved, new study

Their studies: Novartis’s studies of Spondylitis, Ankylosing in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Sanofi 53 of 80 · Novartis 56 of 77 programs (26 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12, Novartis: 7).